Table of Contents

doi : 10.1016/S0923-7534(24)05001-4

Volume 36, Issue 2, February 2025, Pages i-ii

خرید پکیج و مشاهده آنلاین مقاله

Editorial Board

doi : 10.1016/S0923-7534(24)05002-6

خرید پکیج و مشاهده آنلاین مقاله

Expanding the role of CDK4/6 inhibitors in early breast cancer: insights from the NATALEE trial

doi : 10.1016/j.annonc.2025.01.004

خرید پکیج و مشاهده آنلاین مقاله

The immunotherapy challenge in locally advanced gastroesophageal cancer: VESTIGE trial’s insights and future pathways

doi : 10.1016/j.annonc.2024.11.004

خرید پکیج و مشاهده آنلاین مقاله

Estrogens and breast cancer

doi : 10.1016/j.annonc.2024.10.824

خرید پکیج و مشاهده آنلاین مقاله

A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial

doi : 10.1016/j.annonc.2024.10.015

خرید پکیج و مشاهده آنلاین مقاله

TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy☆

doi : 10.1016/j.annonc.2024.10.012

خرید پکیج و مشاهده آنلاین مقاله

Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

doi : 10.1016/j.annonc.2024.10.018

خرید پکیج و مشاهده آنلاین مقاله

Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial

doi : 10.1016/j.annonc.2024.10.828

خرید پکیج و مشاهده آنلاین مقاله

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

doi : 10.1016/j.annonc.2024.10.829

خرید پکیج و مشاهده آنلاین مقاله

A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial

doi : 10.1016/j.annonc.2024.10.827

خرید پکیج و مشاهده آنلاین مقاله

Authors’ reply to the Letters to the Editor discussing main outcomes of the PRODIGE 23 study

doi : 10.1016/j.annonc.2024.10.007

خرید پکیج و مشاهده آنلاین مقاله

Time to rethink platinum choices in the era of immunotherapy in lung cancer

doi : 10.1016/j.annonc.2024.10.009

خرید پکیج و مشاهده آنلاین مقاله

PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?

doi : 10.1016/j.annonc.2024.10.010

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor regarding ‘PFS, OS or toxicity: what is the most important factor in the treatment of EGFR-mutated lung cancer?’ by T. Nishimura and H. Fujimoto

doi : 10.1016/j.annonc.2024.10.011

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor “Odronextamab against relapsed or refractory follicular lymphoma� by Y. Shimazu

doi : 10.1016/j.annonc.2024.10.016

خرید پکیج و مشاهده آنلاین مقاله

Circulating tumor DNA after definitive therapy for locally advanced rectal cancer

doi : 10.1016/j.annonc.2024.10.825

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor ‘Circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima

doi : 10.1016/j.annonc.2024.10.826

خرید پکیج و مشاهده آنلاین مقاله

Promising response to lurbinectedin in NUT carcinoma: a case report and review of emerging therapeutic strategies

doi : 10.1016/j.annonc.2024.10.008

خرید پکیج و مشاهده آنلاین مقاله

Chi-square and P-values versus machine learning feature selection

doi : 10.1016/j.annonc.2024.10.013

خرید پکیج و مشاهده آنلاین مقاله

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

doi : 10.1016/j.annonc.2024.10.014

خرید پکیج و مشاهده آنلاین مقاله